Business Context and Reporting Period
This Form 8-K Current Report was filed by Avalo Therapeutics, Inc. (formerly Cerecor Inc.) on August 26, 2021. The report documents a corporate name change and the associated amendment to the company's Articles of Incorporation and Bylaws.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial performance data.
Material Changes
- Corporate Name Change: Effective August 26, 2021, the company changed its name from Cerecor Inc. to Avalo Therapeutics, Inc.
- Trading Symbol: Common stock began trading on the Nasdaq Capital Market under the new ticker symbol "AVTX" on August 26, 2021.
- Governance Amendments: The Board of Directors approved a Certificate of Amendment to the Amended and Restated Certificate of Incorporation and the Third Amended and Restated Bylaws to reflect the new name. No other changes were made to the Bylaws.
- Stock Certificates: Outstanding certificates for shares of common stock remain valid and do not need to be exchanged.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management commentary on financial outlook, specific risks, contingencies, or unusual items. The document is limited to the procedural details of the name change.
Investor Verification Checklist
- Verify the new ticker symbol "AVTX" on the Nasdaq Capital Market.
- Confirm that existing stock certificates remain valid without exchange.
- Review the full text of the Certificate of Amendment (Exhibit 3.1) and Third Amended and Restated Bylaws (Exhibit 3.2) for any non-name-related provisions.
- Check the press release (Exhibit 99.1) for additional strategic context regarding the rebranding.